Using telehealth to improve access to HIV prevention services for Black and Latino communities
Official title: Telehealth as a Modality to Increase the Uptake of PrEP Services in Black and Latino: "e-PrEP"
Run by Vivent Health · NCT05528653 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study tests if using telehealth can help more Black and Latino men who have sex with men and transgender individuals start and stay on HIV prevention medication by making it easier to access services.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 150 (estimated) |
| Sponsor | Vivent Health Academic / other |
| Locations | 3 sites (Denver, Colorado and 2 other locations) |
| Trial ID | NCT05528653 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are HIV-negative Black and Latino MSM and transgender individuals aged 18 and older who have not used PrEP in the past year.
✕Probably not a fit
Patients who are HIV positive, under 18 years of age, or lack access to the internet or telehealth devices may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of a telehealth model designed to increase the uptake of HIV pre-exposure prophylaxis (PrEP) among Black and Latino men who have sex with men (MSM) and transgender individuals. By offering same-day appointments and navigation support, the study aims to address barriers such as transportation, childcare, and stigma that have historically hindered access to PrEP. The research employs an effectiveness-hybrid design to assess both clinical outcomes and the implementation strategy's success. The hypothesis is that reducing barriers will lead to higher rates of PrEP initiation and persistence in underserved communities.
Why it matters
Potential benefit: If successful, this approach could significantly increase access to HIV prevention services for marginalized populations, ultimately reducing HIV transmission rates.
How similar studies have gone: Other studies have shown promise in using telehealth to improve access to healthcare services, suggesting that this approach may be effective in increasing PrEP uptake.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. HIV negative on any FDA approved HIV test within 10 days of starting PrEP 18 years and older 2. No medical or mental health comorbidity that would preclude participating in a clinical study as deemed by the study investigator 3. Able to understand and sign consent in English or with other language interpreter 4. Able to stay in the state catchment area of the license health care provider 5. No use of PrEP for more than 30 days in the last year Exclusion Criteria: 1. HIV positive 2. If greater and equal to 50 years of age and Renal Glomerular Filtration Rate (GFR) \<30 mg/g 3. \<18 years of age 4. No access to Internet or devise for telehealth 5. Cis-gender Women
Where it's running
-
Vivent Health
Saint Louis, Missouri, United States Recruiting -
Vivent Health
Denver, Colorado, United States Active not recruiting -
Viventh Health
Milwaukee, Wisconsin, United States Active not recruiting
Study contacts
- Principal investigator: Cindy Firnhaber, MD — Vivent Health
- Study coordinator: Billie Thomas
- Email: billie.thomas@viventhealth.org
- Phone: 720-782-5003
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pharmacist-guided PEP/PrEP Access Using PEPPI Software
This trial tests whether the PEPPI software helps pharmacists provide PEP/PrEP and helps patients access these HIV prevention options.
-
Feasibility of Online HIV Prevention Research for People Who Inject Drugs
This study tests whether online recruitment and at-home HIV testing can be done reliably by and for people who inject drugs.
-
Host-led harm reduction for men who have sex with men who engage in chemsex in Bangkok
This project will try a host-led harm reduction approach to reduce substance-related, sexual, mental health, and legal harms among men who have sex with men who engage in chemsex in Bangkok.
-
Transgender-tailored harm reduction and PrEP service for people who engage in chemsex in Bangkok
This project will try a comprehensive harm-reduction service tailored for transgender and non-binary adults in Bangkok who engage in chemsex or substance use to increase PrEP use, reduce HIV/STIs, and address mental health and socio-legal needs.
-
See if PrEP Choice helps young people start and stick with HIV prevention methods
This trial tests whether the PrEP Choice package helps 13-24 year-olds in the U.S. begin and continue using PrEP or DoxyPEP for HIV prevention.
-
Adding sexual-pleasure conversations to harm reduction services for MSM and transgender people who do chemsex in Thailand
This project will try using a 'Pleasuremeter' to guide sexual-pleasure conversations in harm reduction services for MSM and transgender people who engage in chemsex or substance use in Thailand to see if it improves sexual health, substance use, and related outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.